Sanofi Pasteur Inc. agreed to acquire Protein Sciences Corporation from Mertiva AB (publ) (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE) and others for $750 million on July 11, 2017. Under the terms of the agreement, Sanofi will make an upfront payment of $650 million and pay up to $100 million upon achievement of certain milestones. The transaction is subject to customary regulatory approvals and FTC approval. The transaction has been unanimously approved by the Board of Directors of Protein Sciences and a majority of Protein Sciences shareholders. As per announcement made on August 30, 2017, all the conditions et forth for the transaction are met and FTC approved the transaction. The transaction is expected to close in the third quarter of 2017. Michael Aiello, Shayla Harlev, Christina De Vuono, Hayden Guthrie, Aamir Rahman,Brianna Dollinger , Chayim Neubort, Scott Fryman, Amy Rubin, Zahava Blumenthal, Jeffrey Osterman, Jennifer Yoon, Dennis Adams, John Scriber and Christopher Abbott of Weil Gotshal & Manges acted as legal advisors to Sanofi Pasteur Inc.

Sanofi Pasteur Inc. completed the acquisition of Protein Sciences Corporation from Mertiva AB (publ) (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE) and others on August 28, 2017.